[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Northumbria University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":444},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,48,81,98,125,148,173,201,226,244,272,297,326,351,378,415],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100642640","cognitive-task-sensitivity-in-perimenopause-and-nutritional-status-100642640",false,"NCT07648667","Cognitive Task Sensitivity in Perimenopause and Nutritional Status","Pilot Study Assessing Cognitive Task Sensitivity in Perimenopause and Its Association With Nutritional Status","Inclusion Criteria:\n\n* Aged 40-55 years\n* Self-assess as healthy\n* Experienced troublesome perimenopause symptoms for at least the past 6 months (as assessed by the Menopause Rating Scale)\n* Not post-menopause (defined as 12 months with no periods)\n* Non-smoker (including vaping)\n* Not lactating or pregnant (or seeking pregnancy)\n* Oral contraception and hormone replacement therapy allowed if taken for at least 3 months prior\n* Cognitive symptoms\u002Fbrain fog are not required for participation\n\nExclusion Criteria:\n\n* Post-menopause (12 months with no periods)\n* Medically induced perimenopause symptoms\n* Antidepressant\u002Fantianxiety medication or other medication likely to affect cognition in the past 6 months\n* Receiving gender-affirming hormone therapy\n* Nutritional supplementation (apart from vitamin D) within the last month (more than 3 consecutive days or 4 total)",true,"FEMALE","40 Years","55 Years",{"count":21,"type":22},60,"ESTIMATED","OBSERVATIONAL","Perimenopause is when you have symptoms of menopause but your periods have not stopped. Brain-related changes are just one of the many symptoms that occur, and changes to memory and concentration (\"brain fog\") are frequently reported to be a challenge to those experiencing them. Diet is also understood to play an important role during menopause, however there is still more to learn about the direct impact of nutrition on brain-related symptoms associated with perimenopause. The aim of this research is to identify mental tasks capable of capturing perimenopause-related changes and to better understand how diet might account for differences in mental task performance.",[26,27],"Perimenopause","Cognitive Function in Perimenopause",[26,29,30,31,32,33,34],"Cognitive Function","Brain Fog","Diet","Nutrition","Food Frequency Questionaire","Menopause Rating Scale","NOT_YET_RECRUITING","2026-06-12",{"date":38,"type":39},"2026-06-15","ACTUAL",{"date":41,"type":22},"2026-06",{"date":43,"type":22},"2026-07",{"name":45,"class":46},"Northumbria University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100611580","12-week-multi-vitaminmineral-supplementation-on-peri-menopause-symptoms-cognition-sleep-and-psychological-well-being-100611580","NCT07242430","12-week Multi-vitamin\u002FMineral Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being.","Effects of 12-week Multi-vitamin\u002FMineral Supplementation on Peri-menopause Symptoms, Cognition, Sleep and Psychological Wellbeing - a Randomised, Placebo-controlled Trial","Inclusion Criteria:\n\n* Self-assess as healthy\n* Report experiencing troublesome peri-menopause symptoms in the past 6 months but not post-menopausal (defined as 12 months with no periods)\n\nExclusion Criteria:\n\n* Post-menopausal\n* Lactating, pregnant or seeking to become pregnant\n* Nut Allergy\n* Taken antidepressant\u002Fantianxiety medication or other medication with strong likelihood for effects on cognition or sleep in the past 6 months.\n* Habitual multi-vitamin\u002Fmineral supplementation (defined as more than 3 consecutive days or 4 days in total). Will be excluded unless washout for 1 month.\n* Menopause symptoms have been medically induced.\n* Receiving gender-affirming hormone therapy.","60 Years",{"count":57,"type":22},58,"INTERVENTIONAL",[60],"NA","Perimenopause is a stage of transition into menopause that is marked by menopausal symptoms while menstruation is still taking place. Perimenopause symptoms include mood changes, anxiety, sleep disruptions, hot flushes, night sweats, fatigue, and cognitive challenges. The frequency and severity of these symptoms can seriously impair women's quality of life. Even if the public's awareness on menopause has increased, there are still a lot of unanswered questions. A connection between nutrition and menopause management has been proposed in earlier research. However, there is limited research in this field, and women frequently turn to social media for supplement recommendations in order to deal with menopause-related issues.\n\nVitamins and minerals such as vitamin D and calcium are recommended by the European Menopause and Andropause Society and there is limited evidence to suggests that soy and herbals may have a beneficial effect on menopausal symptoms, but more research is needed.\n\nThe aim of this study is to investigate the effects of 12-weeks multi-vitamin\u002Fmineral and herbal extract-containing supplement on menopause symptoms, memory and concentration, sleep, and psychological well-being.",[26,63,64],"Perimenopausal Women","Perimenopause, Climacteric Syndrome",[66,67,68,69,70,71],"perimenopause","cognition","psychological wellbeing","sleep","magnesium","memory","RECRUITING","2026-05-28",{"date":75,"type":39},"2026-05-29",{"date":77,"type":39},"2026-04-07",{"date":79,"type":22},"2026-08-01",{"name":45,"class":46},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":88,"targetDuration":4,"studyType":58,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":97,"locationsCount":47},"100611076","12-week-magnesium-supplementation-on-peri-menopause-symptoms-cognition-sleep-and-psychological-well-being-100611076","NCT07235878","12-week Magnesium Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being","Effects of 12-week Magnesium Supplementation on Peri-menopause Symptoms, Cognition, Sleep and Psychological Wellbeing - a Randomised, Placebo-controlled Trial","Inclusion Criteria:\n\n* Self-assess as healthy\n* Report experiencing troublesome peri-menopause symptoms in the past 6 months but not post-menopausal (defined as 12 months with no periods)\n\nExclusion Criteria:\n\n* Post-menopausal\n* Lactating, pregnant or seeking to become pregnant\n* Nut Allergy\n* Taken antidepressant\u002Fantianxiety medication or other medication with strong likelihood for effects on cognition or sleep in the past 6 months.\n* Habitual magnesium supplementation (defined as more than 3 consecutive days or 4 days in total). Will be excluded unless washout for 1 month.\n* Menopause symptoms have been medically induced.\n* Receiving gender-affirming hormone therapy.",{"count":57,"type":22},[60],"Perimenopause is a transition phase into menopause, characterised by menopausal symptoms while menstrual periods are still occurring. Common symptoms of perimenopause include hot flushes, night sweats, mood swings, anxiety, sleep disturbances, fatigue, and cognitive difficulties. These symptoms can be both frequent and intense, with the potential to significantly deteriorate women's quality of life. Despite an increase in public discourse around menopause, there are still large gaps in knowledge. Previous literature has suggested a relationship between diet and menopause management. However, studies in this area are limited and women often rely on social media for advice on supplements to address menopause complaints. One supplement that has received a lot of attention with purported benefits for menopause is magnesium, primarily due to its links to energy and or\u002Fsleep, however no studies have explored psychological effects of magnesium supplementation in perimenopause.\n\nThe aim of this study is to explore the effects of 12-weeks magnesium supplementation on perimenopause symptoms, cognition, sleep, and psychological well-being.",[26,63,64],[66,67,68,69,70,71],{"date":75,"type":39},{"date":95,"type":39},"2025-12-09",{"date":79,"type":22},{"name":45,"class":46},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":106,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":58,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":122,"leadSponsor":124,"locationsCount":47},"100640649","retraining-gait-in-parkinsons-disease-via-a-personalised-app-100640649","NCT07584993","Retraining Gait in Parkinson's Disease Via a Personalised App","CuePD in the Home: Retraining Gait in Parkinson's Disease Via a Personalised App","CuePD-Extend","Inclusion Criteria:\n\n* Able to walk unaided.\n* Diagnosis of idiopathic Parkinson's.\n* Score ≥21\u002F30 on Montreal Cognitive Assessment (MoCA) which is used to classify non-demented Parkinson's (Parkinson's dementia is \\\u003C21\u002F30).\n* Uses a smartphone.\n\nExclusion Criteria:\n\n* Non-English speakers\n* Use of any mobility aids e.g., walking stick\n* History of stroke, traumatic brain injury or other neurological disorders (other than Parkinson's)\n* Unable to comply with the testing protocol or currently participating in another interfering research project.\n* Does not use a smartphone.\n* Body mass index ≥35 (i.e., severe to morbid obesity)","ALL","50 Years",{"count":109,"type":22},40,[60],"Introduction Parkinson's disease (PD) limits mobility by worsening gait\u002Fwalking and increasing fall risk. Falls lead to injuries and reduce confidence in performing everyday tasks. That lowers a person's ability to participate in community activities such as going to the shops or visiting friends, which reduces their quality of life. Development of interventions for gait impairments and falls is a research priority for Parkinson's UK.\n\nUnderstanding gait Traditionally, one approach a physiotherapist may use to try and improve\u002Fretrain a person's gait is with an electronic metronome which is a device that \"beeps\" nearly every second. The physiotherapist sets the metronome beeping, and the person tries to step to each beep. However, success depends on the physio's expertise\u002Fexperience. Regardless, beeping sounds are described as boring.\n\nSmartphone app An app may be the solution. Smartphones have many sensors, meaning they can accurately measure gait but also deliver retraining via music. That is possible by the creation of an \"app\" that can be downloaded and installed on anyone's smartphone.\n\nResearch proposal The investigators have developed and validated an app (CuePD) that uses music for gait retraining, to make it more enjoyable by having people listen to their preferred music. The aim for this study is to get people with PD (PwPD) using CuePD in their home and when out walking for 12-weeks to determine: (i) how PwPD use and value CuePD and (ii) CuePD's ability to improve gait to reduce fall risk.",[113],"PARKINSON DISEASE (Disorder)",[115,116,117],"Wearables","Personalised cueing","Gait retraining","2026-05-08",{"date":120,"type":39},"2026-05-13",{"date":79,"type":22},{"date":123,"type":22},"2027-12-31",{"name":45,"class":46},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":16,"sex":132,"minAge":133,"maxAge":55,"enrollmentInfo":134,"targetDuration":4,"studyType":58,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":147,"locationsCount":47},"100607952","the-effect-of-lemongrass-on-aerobic-performance-100607952","NCT07195240","The Effect of Lemongrass on Aerobic Performance","The Effect of Lemongrass on Aerobic Performance and Sexual Wellbeing Following High-Intensity Interval Training Training in Males","Inclusion Criteria:\n\n* Age ≥ 40 and ≤ 60 years.\n* Body Mass Index (BMI) ≥ 19 and ≤ 35 kg\u002Fm2.\n* Willingness and ability to comply with the protocol in the opinion of the Investigator.\n* Judged by the Investigator to be in good health as assessed by a health screening questionnaire.\n* Currently identifies as the same biological sex as at birth.\n* Currently deemed to be between a physical activity status of sedentaryy to moderately trained (Meet World Health Organization minimum activity guidelines: Adults aged 18-64 years old completing at least 150 to 300 min moderate-intensity activity or 75-150 min of vigorous-intensity activity a week, plus muscle-strengthening activities 2 or more days a week).\n* Have a blood pressure \\\u003C 140\u002F90 mmHg.\n\nExclusion Criteria:\n\n* A history of heart disease.\n* Any disease that might interfere with the absorption of nutrients (e.g. Chron's disease, celiac disease).\n* Recent musculoskeletal or soft tissue injury (within the last 3 months).\n* The habitual use of medication that is antihypertensive or antidiabetic medication or might inhibit the ability to complete the study participation.\n* Alcohol Intake of greater than 21 units per week.\n* A change in bodyweight of more than 3kg within the month preceding the study.\n* Currently following a weight-loss or weight-gain programme.\n* Any known bleeding disorder or reaction to withdrawal of blood samples","MALE","25 Years",{"count":109,"type":22},[60],"The goal of this experimental study is to examine the influence of Lemongrass extract on aerobic training parameters following a 6-week training programme in males. A secondary aim will be to explore the influence on sexual wellness. Participants will attend 23 visits to the laboratory involving:\n\n* fitness testing (some to exhaustion).\n* blood sampling (capillary and venous samples).\n* a supervised 6 week high-intensity interval training (HIIT) programme.\n* consuming either the lemongrass extract or placebo in the form of tablets, once a day during the 6 week training.",[138,139,140],"Sexual Wellness","Aerobic Capacity","Exercise Efficiency","2026-04-08",{"date":143,"type":39},"2026-04-13",{"date":145,"type":39},"2025-10-24",{"date":41,"type":22},{"name":45,"class":46},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":16,"sex":106,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":58,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":47},"100631509","acute-cardiovascular-effects-of-transcutaneous-auricular-vagus-nerve-stimulation-100631509","NCT07501611","Acute Cardiovascular Effects of Transcutaneous Auricular Vagus Nerve Stimulation","Inclusion Criteria:\n\nParticipants will be eligible if they meet the following criteria:\n\n* Age: 18-45 years\n* Healthy status: No diagnosed cardiovascular, metabolic, neurological, or psychiatric conditions\n* BP: Normotensive (office SBP \\\u003C140 mmHg and DBP \\\u003C90 mmHg)\n* Body Mass Index (BMI): 18.5-30 kg\u002Fm²Non-smoker or light smoker (≤5 cigarettes per day, willing to abstain before testing)\n* Ability to understand and provide written informed consent\n* Willingness to comply with study procedures, including:\n* No regular use of medications affecting cardiovascular or autonomic function (including beta-blockers, calcium channel blockers, antihypertensives, or psychotropic medications)\n\nExclusion Criteria:\n\n* Current participation in another interventional trial\n* Clinically significant resting bradycardia (HR \\\u003C50 bpm)\n* Known damage or surgical removal of the vagus nerve\n* Established cardiovascular disease (e.g., myocardial infarction, heart failure, arrhythmias, stroke, peripheral vascular disease)\n* Diagnosed with hypertension or currently taking antihypertensive medication\n* Known diagnosis of trigeminal neuralgia or other chronic pain conditions\n* Active ear infection or skin conditions affecting the tragus\u002Fauricle\n* Implanted electronic devices (pacemaker, defibrillator, vagal nerve stimulator)\n* Pregnancy or breastfeeding\n* Current diagnosis of anxiety, depression, or other psychiatric conditions requiring medication\n* History of syncope or severe vasovagal response","18 Years","45 Years",{"count":157,"type":22},20,[60],"Introduction\n\nCardiovascular disease (CVD) remains the leading cause of mortality worldwide, with arterial hypertension representing the most significant modifiable risk factor (Lim et al., 2012; Mills et al., 2020). While clinical manifestations of arterial hypertension typically emerge in later life, the underlying pathophysiological mechanisms, particularly autonomic dysfunction, begin decades earlier.\n\nAutonomic imbalance, characterised by sympathetic overactivity and diminished parasympathetic tone, not only precedes sustained arterial hypertension but also independently predicts future cardiovascular risk, even in normotensive individuals (He et al., 2023; Thayer et al., 2010). Reduced heart rate variability (HRV), a non-invasive marker of parasympathetic activity, has been consistently associated with increased cardiovascular morbidity across diverse populations (Task Force, 1996).\n\nCritically, young apparently healthy adults with suboptimal lifestyle factors, including physical inactivity, poor dietary habits, and chronic stress, frequently exhibit reduced HRV and altered sympathovagal balance (Liao et al., 1998). These subclinical autonomic changes represent an early, potentially reversible stage in the cardiovascular disease continuum, suggesting that interventions targeting autonomic balance may prevent or delay progression to overt disease (Goldstein et al., 2011).\n\nThe vagus nerve, the main parasympathetic pathway, exerts multiple cardioprotective effects, including heart rate deceleration, baroreflex enhancement, reduced vascular tone, and anti-inflammatory activity (Thayer \\& Sternberg, 2006). Transcutaneous auricular vagus nerve stimulation (taVNS) has emerged as a non-invasive method to enhance vagal activity by delivering electrical stimulation to the auricular branch of the vagus nerve via surface electrodes placed on the tragus or cymba conchae (Badran et al., 2018). Neuroimaging studies confirm that taVNS activates central vagal projections, including the nucleus tractus solitarius, the primary relay station for cardiovascular autonomic control (Frangos et al., 2015).\n\nPreliminary research demonstrates that acute taVNS sessions increase HRV, enhance baroreflex sensitivity, and reduce sympathetic vascular tone in healthy adults (Clancy et al., 2014; De Couck et al., 2017), while emerging evidence suggests clinically meaningful reductions in blood pressure (BP) in hypertensive patients (Mbikyo et al., 2024).\n\nDespite these promising findings, significant knowledge gaps remain. Most studies have examined clinical populations with pre-existing autonomic abnormalities, making it difficult to isolate primary taVNS mechanisms from disease-related compensatory responses. Additionally, chronic intervention protocols preclude detailed characterisation of immediate autonomic and hemodynamic changes. Conducting mechanistic studies in healthy populations offers critical advantages: absence of confounding medications and disease adaptations enables clearer identification of taVNS-induced autonomic and hemodynamic changes, while establishing baseline response patterns provides an essential reference framework for interpreting clinical population responses and informing preventive interventions. Investigation of acute responses permits precise temporal mapping of physiological changes, distinguishing primary mechanisms from downstream consequences, enables efficient optimisation of stimulation parameters, and provides biological plausibility for chronic effects while identifying potential responders to therapy.\n\nTherefore, this study proposes a randomised, sham-controlled crossover study to systematically characterise acute cardiovascular and autonomic responses to a single 60-minute taVNS session in healthy young adults. Using continuous non-invasive BP monitoring and detailed HRV analysis, this study will establish whether taVNS produces acute, measurable changes in BP, heart rate, and autonomic balance in individuals with normal baseline function. We will elucidate the temporal dynamics of taVNS-induced effects, characterise the mechanistic pathways distinguishing cardiac, hemodynamic, and autonomic contributions, and evaluate the specificity of active stimulation versus sham conditions. By establishing baseline physiological response patterns and elucidating acute mechanisms in a well-controlled population, our findings will lay the groundwork for subsequent investigations in at-risk and hypertensive individuals, ultimately contributing to evidence-based, personalised autonomic modulation therapy for cardiovascular disease prevention and management.",[161],"Vagus Nerve Stimulations",[163,164],"blood pressure","heart rate variability","2026-03-24",{"date":167,"type":39},"2026-03-30",{"date":169,"type":22},"2026-03-01",{"date":171,"type":22},"2027-12-01",{"name":45,"class":46},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":16,"sex":106,"minAge":133,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":58,"phases":183,"briefSummary":184,"conditions":185,"keywords":190,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":47},"100621380","evaluating-the-effects-of-nutritional-interventions-on-sleep-the-gut-microbiome-cognition-and-stress-100621380","NCT07369869","Evaluating the Effects of Nutritional Interventions on Sleep, the Gut Microbiome, Cognition, and Stress.","Evaluating the Effects of Nutritional Interventions on Sleep, the Gut Microbiome, Cognition, and Stress Following 28 Days Consumption in Adults Reporting Sub-clinical Sleep Deficits: A Randomised, Double-blind, Placebo-controlled, Three-arm Parallel Groups Trial.","INCLUSION CRITERIA\n\n* Participants must self-assess themselves as being in good health.\n* Aged 25 to 60 years at the time of randomisation\n* Fluent in English\n* Identify as a 'poor sleeper' as defined subjectively (i.e. poor sleep quality, unrefreshing sleep) and a total score of \\>5 on the Pittsburgh Sleep Quality Index (PSQI).\n\nEXCLUSION CRITERIA\n\n* Member of own household currently participating in this trial\n* Evidence of current or recent sleep disorders (e.g. sleep apnoea, insomnia, circadian rhythm disorders), taking any medication which exerts sedative effects, affects the CNS and\u002For sleep, or be currently unwell with any illness that affects sleep (i.e. disorders of the CNS). An initial screening for sleep disorders will be conducted using the Sleep Disorders Symptom Checklist-25 (SDS-CL; Klingman et al., 2017). If a participant reports positively to any of the 25 questions in terms of being affected for three nights per week, or more, this will be followed up using a clinical interview according to the International Classification of Sleep Disorders (ICSD-3) to exclude on the basis of a sleep disorder\n* History of seizures or epilepsy\n* Shift working or have a history of shift work within the previous six months\n* Currently, or within the previous 8 weeks, consuming any nutritional supplements.\n* Participation in any other intervention research trials\n* Sleeping at a location other than their usual residence more than two nights per week during participation\n* Travel across multiple time zones within the last three months or have planned travel across multiple time zones during the study\n* Current or recent mood disturbances or Axis I disorders (descriptions will be given)\n* Current misuse of alcohol and\u002For drugs\n* Current smoker\n* Recent (within the last 12 weeks) infection and\u002For use of antibiotic medication\n* Pregnant, seeking to become pregnant or lactating\n* Those using (including within the last 2 weeks) proton-pump inhibitors","65 Years",{"count":182,"type":22},68,[60],"This will be a double-blind, placebo-controlled, parallel-group trial. Participants who are poor sleepers will be randomised to receive one of two investigational supplements, or a placebo control supplement, over a 28-day period. At baseline and following 28 days of consumption, sleep quality, gut microbiome profiles, cognitive performance, and mood will be assessed. Sleep outcome measures will also be assessed throughout the supplementation period to monitor the time course of any observed changes. A final data set of at least 66 participants is expected.",[186,187,188,32,189],"Stress","Sleep","Cognition","Microbiome",[69,191,67,192],"gut health","stress","2026-02-27",{"date":195,"type":39},"2026-03-03",{"date":197,"type":22},"2026-05",{"date":199,"type":22},"2026-12",{"name":45,"class":46},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":106,"minAge":107,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":47},"100614604","objective-mobility-assessment-using-wearable-technology-for-clinical-application-in-parkinsons-disease-from-validation-to-fall-prediction-100614604","NCT07281755","Objective Mobility Assessment Using Wearable Technology for Clinical Application in Parkinson's Disease: From Validation to Fall Prediction","Inclusion Criteria:\n\n* Clinical diagnosis of Parkinson's by a movement disorder specialist according to UK brain bank criteria.\n* Hoehn \\& Yahr stages I-III\n* Able to attend Northumbria University, Newcastle Upon Tyne for study visits\n* Able to walk and stand unassisted for a minimum of 2-minutes\n\nExclusion Criteria:\n\n* History of neurological disorders other than PD (e.g., Huntington's disease, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease etc.)\n* Montreal Cognitive Assessment (MoCA) score \\\u003C 21\n* Injury to the lower extremities within the past 6-weeks.",{"count":21,"type":22},"The main objective of this observational trial is to explore the validity and reliability of DANU smart socks when used for mobility assessments in people with Parkinson's. Using a series of laboratory gold standard equipment, this project aims to compare the metrics observed by DANU to the reference standards. No intervention is included. Specifically, this study will explore metrics relating to walking (gait) and balance of a Parkinson's cohort through a series of motor tasks. Moreover, this study seeks to investigate the clinical validity of DANU outcome metrics exploring relationships with clinical scales, fall history and prospective falls.",[210],"Parkinson Disease(PD)",[212,213,214,215,216,217],"DANU","Wearable Electronic Devices","Gait Analysis","Validity and Reliability","Mobility Assessment","Smart Socks","2026-02-11",{"date":220,"type":39},"2026-02-12",{"date":222,"type":39},"2025-08-08",{"date":224,"type":22},"2027-09",{"name":45,"class":46},{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":16,"sex":106,"minAge":107,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":241,"leadSponsor":242,"locationsCount":243},"100614607","clinical-validity-of-the-danu-sports-system-for-gait-and-balance-assessment-in-parkinsons-disease-100614607","NCT07281794","Clinical Validity of the DANU Sports System for Gait and Balance Assessment in Parkinson's Disease","Parkinson's Group Inclusion Criteria:- Clinical diagnosis of Parkinson's by a movement disorder specialist according to UK brain bank criteria.\n\n* PD stages I-III (Hoehn and Yahr Rating Scale)\n* Able to attend Northumbria University, Newcastle Upon Tyne for study visits.\n* Able to walk and stand unassisted for a minimum of 2-minutes.\n* Aged 50 years old or over\n\nParkinson's Group Exclusion Criteria:\n\n* History of neurological disorders other than PD (e.g., Huntington's disease, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease etc.)\n* Unable to walk or stand unaided.\n* Montreal Cognitive Assessment (MoCA) score \\\u003C 21\n* Significant issues unrelated to PD that may affect gait (e.g., musculoskeletal issues, back pain, recent surgery etc.)\n\nHealthy Control Inclusion Criteria:\n\n* Ability to attend Northumbria University, Newcastle Upon Tyne for study visits.\n* Aged 50 years old or over.\n* Able to walk and stand unassisted for a minimum of 2-minutes.\n\nHealthy Control Exclusion Criteria:\n\n* History of neurological disorders (e.g. Huntington's disease, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease etc.)\n* Significant issues that may affect walking (e.g., musculoskeletal issues, back pain, recent surgery etc.)",{"count":21,"type":22},"This observational study aims to explore the use of the DANU Smart Socks for gait and balance assessment in people with Parkinson's (PwP). The study will compare walking and balance outcomes produced by DANU from people with Parkinson's (PwP) and a group of healthy individuals of similar age. The project aims to investigate if the gait and balance data collected are linked to measures of Parkinson's symptoms such as disease progression and cognitive abilities. Gait and balance outcomes will be obtained through one observational laboratory visit.",[235,236],"Parkinson Disease (PD)","Healthy (Controls)",[212,238,213],"Clinical Validation",{"date":220,"type":39},{"date":222,"type":39},{"date":224,"type":22},{"name":45,"class":46},2,{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":106,"minAge":154,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":58,"phases":253,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":47},"100609353","feasibility-and-acceptability-of-isometric-exercise-and-lifestyle-change-for-the-management-of-hypertension-100609353","NCT07213479","Feasibility and Acceptability of Isometric Exercise and Lifestyle Change for the Management of Hypertension","Feasibility and Acceptability of Remote Home-Based Isometric Exercise and Lifestyle Change for the Management of Hypertension","Inclusion Criteria:\n\n* Diagnosis of Arterial Hypertension (AH) in accordance with NICE guidelines.\n* Under pharmacological treatment for AH with antihypertensive drug, type and dose maintained for the previous four months.\n* Blood Pressure with values \\\u003C180 and \\\u003C110 mmHg for office systolic and diastolic BP, respectively.\n* Not currently engaged in any structured or supervised exercise training programme, including resistance, aerobic, or isometric exercise, defined as planned exercise performed ≥2 times per week at moderate or greater intensity, for at least three months prior to enrolment.\n* Written informed consent provided.\n\nExclusion Criteria:\n\n* Body mass index \\>35 kg\u002Fm2.\n* Presence of cardiovascular disease beyond hypertension.\n* Known orthopaedic, musculoskeletal, or neurological conditions that restrain isometric exercise execution.\n* Presence of secondary hypertension\n* Inability to follow verbal instructions or complete study protocol",{"count":252,"type":22},70,[60],"High blood pressure (hypertension) is a leading risk factor for cardiovascular diseases and may contribute to poor health and premature death. The purpose of this research is to learn if a home-based isometric exercise programme combined with lifestyle change advice is a practical and acceptable method for people diagnosed with hypertension to manage their condition. Isometric exercise involves a muscle contraction without movement of the limbs and previous research has shown this may be effective for reducing blood pressure. Therefore, this study will explore the experiences, thoughts, attitudes, and barriers to participation. It will also examine the effect the isometric exercise has on blood pressure.\n\nParticipants will undertake an isometric exercise programme using a wall squat position, 3 times per week, for 12 weeks. The exercise sessions will be completed at home with remote online supervision by an exercise professional. Lifestyle change advice will given in line with current guidelines to promote healthy behaviours to reduce high blood pressure. After 12 weeks, participants will be encouraged to continue with the wall squat exercise for a further 12-weeks unsupervised. Throughout the study, participants' blood pressure and daily activity will be recorded using a smartwatch device.\n\nUpon completion of the intervention period, participants will be interviewed to gather their views and opinions on the isometric exercise programme. Changes in blood pressure will be evaluated at 12 and 24 weeks.\n\nBy exploring whether an isometric exercise programme is a feasible and acceptable method for hypertensive people to manage their condition and how this influences blood pressure, this research may aid in the development of a strategy to manage hypertension.",[256],"Hypertension (HTN)",[258,259,260,261,262,263],"Hypertension","Isometric Exercise","Wall Squat","Cardiovascular Disease","Lifestyle Change","Blood Pressure","2026-02-05",{"date":266,"type":39},"2026-02-06",{"date":268,"type":39},"2026-02-02",{"date":270,"type":22},"2028-02",{"name":45,"class":46},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":16,"sex":106,"minAge":154,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":47},"100615797","evaluating-the-level-of-agreement-between-aamieshiso-universal-standard-requirements-and-the-huawei-d2-watch-type-wrist-blood-pressure-monitor-100615797","NCT07297277","Evaluating the Level of Agreement Between AAMI\u002FESH\u002FISO Universal Standard Requirements and the HUAWEI D2 Watch-Type Wrist Blood Pressure Monitor","An Observational Cross-Sectional Blind Comparison to Evaluate the Level of Agreement Between AAMI\u002FESH\u002FISO Universal Standard Requirements and the HUAWEI D2 Watch-Type Wrist Blood Pressure Monitor","Inclusion Criteria:\n\n* Age \\>18 years\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Cardiac Arrythmias\n* Peripheral Arterial Disease\n* Known Heart Disease\n* Pregnancy\n* Diagnosis of Secondary Hypertension",{"count":280,"type":22},85,"Getting an accurate blood pressure (BP) reading is essential for diagnosing high blood pressure and managing it effectively. High blood pressure is a major health problem, causing about 9.4 million deaths worldwide each year. More people need to monitor their BP at home, so there is greater demand for easy-to-use devices. Traditional BP monitors with arm cuffs can be bulky, uncomfortable, and awkward to use.\n\nModern technology has made it possible to measure BP using wearable devices like smartwatches. HUAWEI has developed a wrist watch that can measure BP and has been tested to meet international standards. The watch passed these tests and was approved for people to use at home to check their own BP. However, the HUAWEI watch was only tested on people in China and the investigators need to know if it works for people from other countries and ethnic backgrounds.",[283],"Blood Pressure Monitoring",[263,285,286,287,288],"Auscultatory","Oscillometric","Watch Type Monitor","Validation","2025-12-22",{"date":291,"type":39},"2025-12-30",{"date":293,"type":39},"2025-07-15",{"date":295,"type":22},"2027-10",{"name":45,"class":46},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":16,"sex":106,"minAge":303,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":58,"phases":306,"briefSummary":307,"conditions":308,"keywords":312,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":325,"locationsCount":47},"100596564","investigation-of-the-acute-effects-of-nepalese-pepper-extract-zanthoxylum-armatum-dc-on-cognitive-function-mood-and-gaming-performance-in-young-healthy-competitive-gamers-100596564","NCT07047105","Investigation of the Acute Effects of Nepalese Pepper Extract (Zanthoxylum Armatum DC) on Cognitive Function, Mood and Gaming Performance in Young, Healthy, Competitive Gamers","Inclusion Criteria:\n\n* Aged 16 to 34 years inclusive\n* Males and females\n* Self-report of good health\n* Usually a regular (at least once per week) player of competitive multiplayer games, (prospective participants will be asked to contact the researchers to discuss their gaming habits if uncertain that they meet the criteria).\n\nExclusion Criteria:\n\n* Have any pre-existing medical condition\u002Fillness which will impact taking part in the study (i.e. participants may be allowed to progress to screening if they have a condition\u002Fillness which would not interact with the active treatments or impede performance).\n* Are currently taking prescription medications NOTE: the explicit exceptions to this are contraceptive treatments for female participants, and those taken 'as needed' in the treatment of asthma and hay fever. There may be other instances of medication use which, where no interaction with the active treatments is likely, and which would not be expected to have any impact on brain function, participants may be able to progress to screening.\n* Have high blood pressure (systolic over 139 mm Hg or diastolic over 89 mm Hg); or have low blood pressure (systolic below 90 mm Hg or diastolic below 60 mm Hg)\n* Have a Body Mass Index (BMI) outside of the range 18.5-35 kg\u002Fm2\n* Are pregnant, seeking to become pregnant or lactating\n* Have learning and\u002For behavioural diagnoses such as dyslexia or ADHD\n* Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness)\n* Smoke tobacco or vape nicotine or use nicotine replacement products\n* Excessive caffeine intake (\\> 500 mg per day). If participants consume energy drinks they will be asked to refrain from this for 24 hour prior to attending testing.\n* Have relevant food intolerances\u002Fsensitivities, including caffeine sensitivity.\n* Have taken antibiotics within the past 4 weeks\n* Have taken dietary supplements e.g. Vitamins, omega 3 fish oils etc. in the last 4 weeks (Note: participation is possible following a 4-week supplement washout prior to participating and for the duration of the study on the proviso that the supplements they are taken are out of choice and not medically prescribed or advised)\n* Have any health condition that would prevent fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken)\n* Are unable to complete all of the study assessments\n* Are currently participating in other clinical or nutrition intervention studies, or have done so in the past 4 weeks\n* Has been diagnosed with\u002F undergoing treatment for alcohol or drug abuse in the last 12 months\n* Have been diagnosed with\u002F undergoing treatment for a psychiatric disorder in the last 12 months\n* Suffers from frequent migraines that require medication (more than or equal to 1 per month)\n* Sleep disorders or are taking sleep aid medication\n* Any known active infections\n* Are non-compliant with regards treatment consumption","16 Years","34 Years",{"count":21,"type":22},[60],"The goal of this clinical trial is to learn if a Nepalese Pepper Extract (Zanthoxlum Armatum, ZA) supplement can improve cognitive performance and mental abilities in competitive gamers aged 16 to 34. The main questions it aims to answer are:\n\n1. Does ZA supplement improve cognitive abilities like attention, memory, and decision-making?\n2. What is the most effective dose of ZA supplement (300mg vs 150mg)?\n3. How do the effects of ZA supplement compare to caffeine?\n\nResearchers will compare four different treatments (high-dose ZA, low-dose ZA, caffeine, and placebo) to see if ZA supplement produces better cognitive performance than placebo and how it compares to caffeine\\*\\*.\n\nParticipants will:\n\n* Complete a screening visit with health checks and training on computer tasks\n* Attend four testing visits (7-14 days apart) where they receive different treatments\n* Avoid alcohol and energy drinks for 24 hours before each visit, and caffeine from waking\n* Take assigned treatment at 11:30am and complete cognitive tests at -1, 1, 3, and 5 hours in relation to dose.\n* Complete mood questionnaires, sleep assessments, and gaming-specific tasks (aim training, character control)\n* Wear heart rate monitors during testing\n* Eat standardized meals provided during visits\n* Play competitive games at home in the evening and complete performance questionnaires",[188,309,310,311],"Mood","Gaming Performance","Fatigue",[188,309,313,314,315,316,317,318,311],"Gaming","Performance","Esports","Nepalese Pepper","Timut Pepper","Zanthoxylum Armatum","2025-06-23",{"date":321,"type":39},"2025-07-02",{"date":323,"type":39},"2025-06-13",{"date":197,"type":22},{"name":45,"class":46},{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":16,"sex":106,"minAge":154,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":58,"phases":336,"briefSummary":337,"conditions":338,"keywords":341,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":47},"100576091","investigating-the-acute-and-chronic-effects-of-a-supplement-containing-caffeine-vitamins-minerals-and-botanical-extracts-on-cognition-sleep-and-wellbeing-in-healthy-volunteers-100576091","NCT06780774","Investigating the Acute and Chronic Effects of a Supplement Containing Caffeine, Vitamins, Minerals and Botanical Extracts on Cognition, Sleep and Wellbeing, in Healthy Volunteers","Investigating the Acute and Chronic Effects of a Supplement Containing Caffeine, Vitamins, Minerals and Botanical Extracts on Cognition, Sleep and Wellbeing, in Healthy Volunteers.","Inclusion Criteria:\n\n* You self-assess yourself as being in good health.\n* You are aged 18-75 years at the time of giving consent.\n* English is your first language or are fluent in English.\n\nExclusion Criteria:\n\n* Insufficient (\\\u003C 40 mg per day) or excessive (\\> 500 mg per day) habitual caffeine consumption (\\* NOTE: This will be calculated at screening but feel free to query this with the researcher prior to attendance.).\n* Have any pre-existing medical conditions\u002Fillnesses which will impact taking part in the study. (\\* NOTE: The explicit exceptions to this are controlled hyper\u002Fhypothyroidism, hay fever, high cholesterol and reflux-related conditions. NOTE: There may be other, unforeseen, exceptions and these will be considered on a case-by-case basis, i.e. participants may be allowed to progress to screening if they have a condition\u002Fillness which would not interact with the active treatments or impede performance so it's worth discussing any medical conditions with the researcher prior to booking lab appointments).\n* Are currently taking prescription medications which will impact taking part in the study (\\* NOTE: the explicit exceptions to this are contraceptive treatments for female participants, thyroid medications, topical skin treatments and those medications used in the treatment of high cholesterol and reflux-related conditions; and those taken 'as needed' in the treatment of asthma and hay fever.).\n* Have high blood pressure (systolic over 139 mm Hg or diastolic over 89 mm Hg1) - \\*NOTE: We must measure this in the lab using our blood pressure monitors and can only use our measurements to access eligibility rather than home or GP readings.\n* Have a Body Mass Index (BMI) outside of the range 18.5-39.9 kg\u002Fm2.\n* Are pregnant, seeking to become pregnant or lactating.\n* Have been diagnosed with a neurological condition or assessed as having a learning\u002Fbehavioural or neurodevelopmental difference (e.g. dyslexia, autism, ADHD).\n* Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness).\n* Smoke tobacco\u002F vape nicotine\u002F use nicotine replacement products (\\* NOTE: If participants have recently quit smoking or using replacements, they must have stopped using them altogether for a period of 3 months before participating in this study).\n* Have relevant food allergies\u002F intolerances\u002F sensitivities (Please discuss all allergies\u002F intolerances\u002F sensitivities with the researcher prior to your screening appointment).\n* Have taken antibiotics within the past 4 weeks.\n* Are currently consuming any other dietary supplement (e.g., vitamins, omega 3 fish oils etc.) or have done so in the last 4 weeks. (\\* NOTE: Participation is possible following a 4-week supplement wash out prior to participating and for the duration of the study on the proviso that the supplements they are taking are out of choice and not medically prescribed or advised. Please discuss with the researcher if unsure. NOTE: We would never advise stopping supplements prescribed by your doctor e.g., iron, calcium etc., only those you use out of choice).\n* Have any health conditions that would prevent the fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken).\n* Are unable to complete all of the study assessments (this will be assessed by the researcher at your training appointment, whereby you must be able to reach the minimum scores for each cognitive task to progress with the trial).\n* Are currently participating in another clinical or nutrition intervention study or have done so in the past 4 weeks.\n* Have been diagnosed with\u002F undergoing treatment for alcohol or drug abuse in the last 12 months.\n* Have been diagnosed with\u002F undergoing treatment for a psychiatric disorder in the last 12 months, including a medical diagnosis of anxiety or depression.\n* Suffer from frequent migraines that require medication (more than or equal to 1 per month).\n* Have any sleep disorders or take any sleep aid medications.\n* Have any known active infections.\n* Will be non-compliant with regards to treatment consumption.\n* Does not have a bank account (required for payment).","75 Years",{"count":335,"type":22},90,[60],"The aim of the study is to investigate the acute and chronic effects of a supplement containing Caffeine, Vitamins, Minerals and Botanical extracts on cognitive function, sleep and wellbeing, in healthy volunteers.\n\nThe study will follow a randomised, double-blind, placebo-controlled, crossover design. Participants will receive both treatments, and both study arms will include an acute testing visit (day 1) and a chronic testing visit (day 29). The active treatment contains a blend of 120mg caffeine, vitamins, minerals and botanical extracts and the matched placebo treatment contains marigold extract and brown rice flour.\n\nThe trial will use computerised cognitive tasks, administered via COMPASS software (Northumbria University, UK), online cognitive assessments via Cognimapp and self-reported questionnaires and sleep diary, as measures of the outcome variables.\n\n90 participants will participate, aged 18-75, and self-ported as being in good health. Participants will be randomly allocated to a treatment order and will be supplied with either the active treatment or the placebo whilst visiting the research centre for the acute testing visits. Participants will take the treatment home to consume daily for the duration of the supplementation period. Participants will record the time of taking treatment each day in a treatment diary which will be returned to the research centre, along with any unused treatment, at each chronic testing visit.",[339,187,29,340,309],"Caffeine","Wellbeing",[339,342,187,340,309],"Cognitive function","2025-02-06",{"date":345,"type":39},"2025-02-10",{"date":347,"type":22},"2025-02-24",{"date":349,"type":22},"2025-12-19",{"name":45,"class":46},{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":16,"sex":106,"minAge":133,"maxAge":357,"enrollmentInfo":358,"targetDuration":4,"studyType":58,"phases":359,"briefSummary":360,"conditions":361,"keywords":365,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":375,"leadSponsor":377,"locationsCount":4},"100567106","investigating-the-effects-of-dairy-phospholipids-on-sleep-and-daytime-function-in-healthy-adults-100567106","NCT06663865","Investigating the Effects of Dairy Phospholipids on Sleep and Daytime Function in Healthy Adults.","Inclusion Criteria:\n\n* Participants must self-assess themselves as being in good health.\n* Participants must be aged 25 to 49 years at the time of giving consent.\n* Participants must be a native speaker of English or fluent in English\n\nExclusion Criteria:\n\n* Have any pre-existing medical conditions\u002Fillness which will impact taking part in the study. There may be other, unforeseen exceptions and these will be considered on a case-by-case basis: i.e., participants may be allowed to progress to screening if they have a condition\u002Fillness which would not interact with the active treatments or impede performance. It is therefore worth discussing any medical conditions with the researcher prior to booking appointments\n* Are currently taking any prescription medications (NOTE the explicit exceptions to this are contraceptive treatments for female participants, and those taking \"as needed\" in the treatment of asthma and\u002For hay fever. There may be other instances of medication use which, where no interaction with the active treatment is likely, and which would not be expected to have any impact on brain function, participants may be able to progress to screening\n* Have high blood pressure (systolic over 159 mm Hg or diastolic over 99 mm Hg). NOTE: that we must measure this in the lab using our blood pressure monitors and can only use our measurements to assess eligibility rather than home or GP readings\n* Have a Body Mass Index (BMI) outside of the range 18.5-35 kg\u002Fm2.\n* Are pregnant, seeking to become pregnant or lactating.\n* Have learning and\u002For behavioural difficulties such as dyslexia or ADHD.\n* Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness)\n* Smoke tobacco or vape nicotine or use nicotine replacement products (if you have recently quit smoking or using replacements you must have stopped using them altogether for a period of 3 months before participating in this study)\n* Have excessive caffeine intake (500 mg per day). Note: This will be calculated at screening but feel free to query this with the researcher prior to attendance\n* Have relevant food allergies\u002F intolerance\u002F sensitivities\n* Have taken antibiotics within the past 4 weeks.\n* Have taken dietary supplements e.g., vitamins, omega 3 fish oils etc. in the last 4 weeks (Note: participation is possible following a 4 week supplement wash out prior to participating and for the duration of the study on the proviso that the supplements they are taking are out of choice and not medically prescribed or advised. Please discuss with the researcher if unsure. NOTE: we would never advise stopping supplements prescribed by your doctor e.g., iron, calcium etc., only those you use out of choice)\n* Have any health condition that would prevent fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken)\n* Are unable to complete all of the study assessments (this will be assessed by the researcher at the training appointment)\n* Are currently participating in other clinical or nutrition intervention studies, or have in the past 4 weeks\n* Have been diagnosed with\u002F undergoing treatment for alcohol or drug abuse in the last 12 months.\n* Have been diagnosed with\u002F undergoing treatment for a psychiatric disorder in the last 12 months, including a medical diagnosis of anxiety or depression.\n* Suffers from frequent migraines that require medication (more than or equal to 1 per month)\n* Have any sleep disorders or take any sleep medications.\n* Routinely work night shifts\n* Have any known active infections.\n* Does not have a bank account (required for payment)\n* Are non-compliant with regards treatment consumption\n* Follow an \"extreme\" or very \"strict\" diet i.e., Keto, very high protein, sugar free, raw paleo etc.\n* Are planning a major lifestyle change regarding diet or exercise regime in the next 3 months.\n* Experienced an event (professional or personal) that is likely to have impacted your emotional and\u002For psychological state within the last 8-10 weeks (for example but not restricted to change of professional function, death of a family member, divorce, surgery, accident etc)\n* Have an upcoming event (personal or professional) that is likely to affect your emotional, psychological state or hormonal state planned during the next 8-10 weeks, including but not limited to job change, house move, important medical exam etc.\n* Have any oral disease such as gingivitis\n* Are planning any overseas travel with significant time zone differences","49 Years",{"count":252,"type":22},[60],"The aim of the study is to investigate the effects of 6- and 12- week supplementation of a bioactive whey protein concentrate drink containing dairy phospholipids on sleep and daytime function parameters in healthy adults.\n\nThe proposed randomised, double-blind, placebo-controlled parallel groups design methodology will assess the sleep and daytime function effects (both self-reported and physiological) of 40g per day of bioactive whey protein concentrate in the form of a powder that the participant will be required to mix with 350ml of water and matched placebo prior to (baseline) and after -6 week and -12 week supplementation. The trial will utilise actigraphy sleep watches and online cognitive assessments alongside saliva sampling, sleep diaries, and self-report questionnaires as measures of the outcome variables.\n\n70 participants will participate, aged 25-49, and self-reported as being in good health. Participants will be supplied with either the active treatment or the placebo (allocated by a randomised schedule) whilst visiting the research centre for the testing appointments and will take treatment home to consume daily for the duration of the study. Participants will record time of taking treatment each day in a treatment diary which will be returned to the research centre, along with any unused treatment, upon completion of the study.",[187,362,363,364],"Morning Alertness","Evening Alertness","Diurnal Cortisol",[187,366,367,368,369,370],"Daytime function","diurnal cortisol","Morning alertness","Evening alertness","dreams","2024-10-28",{"date":373,"type":39},"2024-10-29",{"date":371,"type":22},{"date":376,"type":22},"2025-06-27",{"name":45,"class":46},{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":106,"minAge":180,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":4},"100552444","mobility-assessment-in-multi-morbidity-100552444","NCT06473168","Mobility Assessment in Multi-morbidity","Walking-related Mobility Assessment in Older People With Multimorbidity","Multi-mobility","Inclusion Criteria:\n\n* Adults ≥65 years old\n* Able and willing to provide informed consent\n* Able to read and write in English\n* To be mobile (including the use of walking aids)\n* Two or more of the following long terms conditions: Arthritis, Asthma, Atrial fibrillation, Bronchiectasis, Cancer, Chronic kidney disease, Chronic obstructive pulmonary disease, Coronary heart disease, Anxiety, Depression, Diabetes mellitus, Heart failure, Hypertension, Osteoporosis, Parkinson's disease, Peripheral vascular disease, Stroke or transient ischaemic attack\n\nExclusion Criteria:\n\n* Unable to give consent for the study\n* Severe mental health problems\n* Active malignancy (on chemotherapy\u002Fradiotherapy\u002Fplanned urgent surgery)",{"count":387,"type":22},55,"Multimorbidity (the presence of two or more coexisting long-term conditions) is a significant challenge facing the NHS, especially given UK's ageing population and the association with high levels of illness burden and healthcare costs. Over 50% of adults \\>65 years have multiple long-term conditions (MLTCs).\n\nOur group has validated a broad range of algorithms applied to single wearable sensors that have the potential to capture walking-related mobility outcomes (such as walking cadence and walking speed) accurately and reliably during activities of daily living across five single long-term conditions. These algorithms, however, cannot be readily applied to people with MLTCs because the effect of multimorbidity on mobility is amplified compared to single long-term conditions secondary to a greater number of complications and sequelae. Accordingly, the aim of this study is to validate algorithms that would allow robust estimation of walking-related mobility outcomes during daily life activities in MLTCs.\n\nTo meet our objectives, the investigators will perform: i) laboratory-based technical validation of existing and newly developed algorithms for walking-related mobility outcome detection; ii) unsupervised real-life validation of selected algorithms; and iii) examination of how well the validated walking-related mobility outcomes reflect global and disease specific characteristics in older adults with multimorbidity. The investigators will adopt an integrated patient-centric approach where patients with MLTCs will be engaged early in the project to provide input of their perception and concerns regarding mobility limitation in daily life activities.\n\nThe investigators aim to recruit 55 older adults (\\>65 years), men and women, with multiple long-term conditions with the following inclusion criteria: having two or more of the following conditions including osteoarthritis, rheumatoid arthritis, osteoporosis, type 2 diabetes, depression and\u002For anxiety, hypertension, coronary heart disease, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, asthma, bronchiectasis, chronic kidney disease, cancer, or stroke within the last 5 years.",[390,391,392,393,394,395,396,397,398,399,400,401,258,402,403,404,405,406],"Arthritis","Asthma","Atrial Fibrillation","Bronchiectasis","Cancer","Chronic Kidney Diseases","Chronic Obstructive Pulmonary Disease","Coronary Heart Disease","Anxiety","Depression","Diabetes Mellitus","Heart Failure","Osteoporosis","Parkinson Disease","Peripheral Vascular Disease","Stroke","Transient Ischemic Attack","2024-06-18",{"date":409,"type":39},"2024-06-25",{"date":411,"type":22},"2024-12-01",{"date":413,"type":22},"2025-12-31",{"name":45,"class":46},{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":16,"sex":106,"minAge":55,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":58,"phases":424,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":47},"100550505","keep-exercising--stay-steady-development-and-feasibility-of-a-digital-health-intervention-to-encourage-exercise-maintenance-after-fall-prevention-exercise-programmes-end-100550505","NCT06447948","Keep Exercising & Stay Steady: Development and Feasibility of a Digital Health Intervention to Encourage Exercise Maintenance After Fall Prevention Exercise Programmes End.","Keep Exercising & Stay Steady (KESS): Development and Feasibility of a Digital Health Intervention to Encourage Exercise Maintenance After Fall Prevention Exercise Programmes End","KESS","Eligibility criteria:\n\n* Community dwelling older adults, aged over 60 years old.\n* Enrolled on a Healthworks FaME programme in the Northeast region of England.\n* Able to provide informed written consent.\n\nExclusion criteria:\n\n* Unable to independently walk 5 metres without a walking aid.\n* Advised by a medic not to undertake exercise.\n* Has a medical, cognitive, or physical condition that prevents safe engagement with digital technology or unsupervised exercise.",{"count":109,"type":22},[60],"Falls and broken bones are a common health problem faced by older adults. Worldwide, one third of adults aged over 65 years old, and half of adults aged over 80 years, fall each year. One in five falls in older adults result in hospitalisation and one in twenty cause broken bones. Each year, 300,000 older adults break a bone following a fall which costs the UK £4.4billion in healthcare costs. Broken hip bones are the most serious outcome of a fall. One in twenty older adults will die and one in five need care assisted living following a hip fracture.\n\nMuscles and bones become weaker after 50 years of age which increases an older adults' risk of falling and breaking a bone. Falls prevention programmes that include muscle strength and balance exercise improves physical function and helps to prevent falls and broken bones in older adults. However, many older adults stop doing exercise and become less physically active after falls prevention programmes end. Gains in balance and muscle strength are lost and falls risk increase if people don't keep exercising. More people are reaching older ages and becoming less active. Therefore, this problem will worsen unless healthcare practices become better at preventing falls and broken bones in older adults.\n\nThe research ambition is to create a technology supported home exercise programme that encourages older adults to keep exercising after falls prevention programmes end. This will help to prevent future falls and broken bones which will allow more older adults to continue living independently. The home exercise programme will benefit older adults everyday lives by helping them to maintain good physical health and improve their ability to perform daily tasks without the fear of falling.\n\nOlder people at risk of falls, clinicians, and public members will be invited to form a research advisory group. The group will work with the research team to create the home exercise programme and research plan and advise how best to communicate the research to the public. Diversity within the research advisory group will be important to help shape the research to meet the diverse views and needs of the many different people affected by falls and broken bones. We will target the research to help older adults with the greatest health needs. Older adults living in deprived neighbourhoods have the greatest risk of falling and dying following a broken bone. The home exercise programme will be researched in older adults attending falls prevention programmes in the most deprived regions of England. This will help us to explore whether the programme could encourage the continuation of exercise in older adults who need it most.",[427],"Fall Patients",[429,430,431,432,433,434,435],"Falls Prevention","Ageing Health","Physical activity","Exercise Maintenance","Behaviour Change","Digital health","Older Adults","2024-06-03",{"date":438,"type":39},"2024-06-07",{"date":440,"type":22},"2024-06-20",{"date":442,"type":22},"2026-05-19",{"name":45,"class":46},""]